Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594580 | 0.83 | CPB2 (0.42) | CPB2CPB1 | |
| SCHEMBL1071999 | 0.82 | CPB2 (0.40) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL11418503 | 0.81 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL1521823 | 0.81 | CPB2 (0.41) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL3428343 | 0.80 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL14571377 | 0.79 | LPO (0.37) | CPB2CPB1 | |
| SCHEMBL6975846 | 0.79 | CYP3A4 (0.32) | CPB2CPB1 | |
| SCHEMBL30786466 | 0.75 | CPB2 (0.37) | CPB2CPB1 | |
| SCHEMBL21095371 | 0.73 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL15726438 | 0.72 | CPB2 (0.38) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1909780-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | Sequella, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007005896-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| EP-1513825-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Department of Health and Human Services (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | CPB2 1706/4885CPB1 2070/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | CPB2 3476/4885CPB1 3926/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | CPB2 1450/4885CPB1 1711/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | CPB2 3296/4885CPB1 3424/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | CPB2 3296/4885CPB1 3424/4885 |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | CPB2 3296/4885CPB1 3424/4885 |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | TYMS, TERT, TYMP | CPB2 2970/4885CPB1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.